Skip to Content

Braftovi Approval History

FDA Approved: Yes (First approved June 27, 2018)
Brand name: Braftovi
Generic name: encorafenib
Dosage form: Capsules
Company: Array BioPharma Inc.
Treatment for: Melanoma, Metastatic

Braftovi (encorafenib) is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Development History and FDA Approval Process for Braftovi

DateArticle
Jun 27, 2018Approval Array BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide